Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of spironolactone on residual kidney function in incremental hemodialysis patients
TCTR20260227007Phase 4Recruiting
- Sponsor
- Bhumibol Adulyadej Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of spironolactone in end-stage kidney disease (ESKD) (2 arms), sponsored by Bhumibol Adulyadej Hospital. Primary endpoint: Change in residual kidney function. Started Sep 2025; status: recruiting.
02
Drugs
spironolactone
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20260227007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260227007.